Iris C. Kok

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge et al. · Nature Medicine · 2018 · 734 citations · Full text

Medicine, Oncology, Pharmacology +17

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

Iris C. Kok, J.S. Hooiveld, Pim P. van de Donk et al. · Annals of Oncology · 2021 · 95 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Kirsten L. Moek, Stijn J.H. Waaijer, Iris C. Kok et al. · Clinical Cancer Research · 2019 · 54 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, Danique Giesen et al. · Clinical Cancer Research · 2021 · 44 citations · Full text

Medicine, Nuclear Medicine, Pharmacology +17

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Saskia H. Hanemaaijer, Iris C. Kok, Rudolf S.N. Fehrmann et al. · Frontiers in Oncology · 2020 · 30 citations · Full text

Medicine, Oncology, Radiation Oncology +13